Skip to main content
OpenTrials
Completed

NCT Number: NCT02662764

Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg

Study to evaluate the overall performance of the Zalviso System™ (sufentanil sublingual tablet system) 15 mcg

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Moderate-to-severe Acute Pain

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Eliza Coffee Memorial Hospital, Florence, Alabama, United States

Loading trial locations.

About this study

320 adult postoperative in-patients, who met all study entry requirements, and were expected to require opioid analgesia for at least 24 hours, and up to 72 hours, after surgery were enrolled. Patients used the Zalviso™ (sufentanil sublingual tablet system) 15 mcg to self-administer a tablet of study drug as needed for pain. The System was evaluated for usability and functionality for up to 72 hours.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female patients who were 18 years of age or older.
  • Patients who were scheduled to undergo surgery under general or spinal anesthesia that does not include intrathecal opioids during the operation.
  • Patients classified as American Society of Anesthesiologists (ASA) class I - III (Appendix I).
  • Female patients of childbearing potential must have been using an effective method of birth control at the time of screening visit and for 30 days following the end of the study period. Acceptable methods of birth control included oral or transdermal contraceptives, condom, spermicidal foam, intrauterine device (IUD), progestin implant or injection, abstinence, vaginal ring, or sterilization of partner. The reason for non-child bearing potential, such as bilateral tubal ligation, bilateral oophorectomy, hysterectomy, or postmenopausal for > 1 year, was specified. Patients using hormonal forms of contraception were also willing to use a barrier method of contraception from screening through 30 days following the study period.
  • Post-surgical patients who had been admitted to the PACU, and were expected to have acute pain requiring opioids for 24 - 72 hours after surgery.

Exclusion criteria

  • Patients who had taken an opioid for more than 30 consecutive days, at a daily dose of 15 mg or more of morphine (or equivalent), within the past 3 months prior to surgery (e.g. more than 3 doses per day of Vicodin®, Norco®, Lortab® with 5 mg hydrocodone per tablet).
  • Patients who were currently taking monoamine oxidase inhibitors (MAOIs) or had taken MAOIs within 14 days of the first dose of study drug.
  • Patients with current sleep apnea that had been documented by a sleep laboratory study or were on home continuous positive airway pressure (CPAP).
  • Patients with an allergy or hypersensitivity to opioids.
  • Patients who were currently taking monoamine oxidase inhibitors (MAOIs) or had taken MAOIs within 14 days of the first dose of study drug.
  • Patients with current sleep apnea that had been documented by a sleep laboratory study or were on home continuous positive airway pressure (CPAP).
  • Patients who were receiving oxygen therapy at the time of screening.

Treatment and study plan

Zalviso™ 15 mcg

Drug

Zalviso™ (sufentanil sublingual tablet system) 15 mcg. Tablets to be self-administered by the patient as needed for pain, no more than every 20 minutes, for 24 hours and up to 72 hours

Other names: Zalviso™ (sufentanil sublingual tablet system) 15 mcg

Primary outcomes

  1. Percentage of Patients Who Experienced at Least One System-generated Error Based on the Controller Data While Using the Zalviso System

    Time frame: Up to 72 hours

  2. Percentage of Patients, if Any, With Tablets Dispensed But Not Requested

    Time frame: Up to 72 hours

  3. Percentage of Patients, if Any, With Tablet Dispensed When the Zalviso System Was in Lockout

    Time frame: Up to 72 hours

  4. Percentage of Patients With Misplaced Tablet(s)

    Time frame: Up to 72 hours

  5. Number of Misplaced Tablets (i.e., Tablet Found Outside the Patient's Mouth)

    Time frame: Up to 24 hours

  6. Percentage of Patients Who Experienced Either a System-generated Error or a Misplaced Tablet (i.e., a Dispense Failure)

    Time frame: Up to 72 hours

  7. Number of Zalviso System Notifications to the Nurse to Retrain Patient to Not Pull Down on the Controller While Dosing

    Time frame: Up to 72 hours

  8. Percentage of Patients Who Experienced Either a System-generated Error or a Misplaced Tablet That Caused an Analgesic Gap

    Time frame: Up to 72 hours

  9. Percentage of Patients Who Rate the Patient Global Assessment (PGA) of Method of Pain Control Over 24 Hours as "Good" or "Excellent"

    Time frame: Up to 24 hours

  10. Percentage of Patients Who Rate the Patient Global Assessment (PGA) of Method of Pain Control Over 48 Hours as "Good" or "Excellent"

    Time frame: Up to 48 hours

  11. Percentage of Patients Who Rate the Patient Global Assessment (PGA) of Method of Pain Control Over 72 Hours as "Good" or "Excellent"

    Time frame: Up to 72 hours

  12. Percentage of Patients Who Responded to the Patient Global Assessment (PGA) as "Poor" at 24 Hours

    Time frame: Up to 24 hours

  13. Percentage of Patients Who Responded to the Patient Global Assessment (PGA) as "Fair" at 24 Hours

    Time frame: Up to 24 hours

  14. Percentage of Patients Who Responded to the Patient Global Assessment (PGA) as "Good" at 24 Hours

    Time frame: Up to 24 hours

  15. Percentage of Patients Who Responded to the Patient Global Assessment (PGA) as "Excellent" at 24 Hours

    Time frame: Up to 24 hours

  16. Percentage of Patients Who Responded to the Patient Global Assessment (PGA) at 48 Hours as "Poor"

    Time frame: Up to 48 hours

  17. Percentage of Patients Who Responded to the Patient Global Assessment (PGA) at 48 Hours as "Fair"

    Time frame: Up to 48 hours

  18. Percentage of Patients Who Responded to the Patient Global Assessment (PGA) at 48 Hours as "Good"

    Time frame: Up to 48 hours

  19. Percentage of Patients Who Responded to the Patient Global Assessment (PGA) at 48 Hours as "Excellent"

    Time frame: Up to 48 hours

  20. Percentage of Patients Who Responded to the Patient Global Assessment (PGA) at 72 Hours as "Poor"

    Time frame: Up to 72 hours

  21. Percentage of Patients Who Responded to the Patient Global Assessment (PGA) at 72 Hours as "Fair"

    Time frame: Up to 72 hours

  22. Percentage of Patients Who Responded to the Patient Global Assessment (PGA) at 72 Hours as "Good"

    Time frame: Up to 72 hours

  23. Percentage of Patients Who Responded to the Patient Global Assessment (PGA) at 72 Hours as "Excellent"

    Time frame: Up to 72 hours

  24. Percentage of Healthcare Professionals (HCPs) Who Rated the Healthcare Professional Global Assessment (HPGA) of Method of Pain Control Over 24 Hours as "Good" or "Excellent"

    Time frame: Up to 24 hours

  25. Percentage of Healthcare Professionals (HCPs) Who Rate the Healthcare Professional Global Assessment (HPGA) of Method of Pain Control Over 48 Hours as "Good" or "Excellent"

    Time frame: Up to 48 hours

  26. Percentage of Healthcare Professionals (HCPs) Who Rated the Healthcare Professional Global Assessment (HPGA) of Method of Pain Control Over 72 Hours as "Good" or "Excellent"

    Time frame: Up to 72 hours

  27. Percentage of Healthcare Professional (HCPs) Who Responded to the Healthcare Professional Global Assessment (HPGA) as "Poor" at 24 Hours

    Time frame: Up to 24 hours

  28. Percentage of Healthcare Professional Global Assessment (HCPs) Who Responded to the Healthcare Professional Global Assessment (HPGA) as "Fair" at 24 Hours

    Time frame: Up to 24 hours

  29. Percentage of Healthcare Professionals (HCPs) Who Responded to the Healthcare Professional Global Assessment (HPGA) as "Good" at 24 Hours

    Time frame: Up to 24 hours

  30. Percentage of Healthcare Professional (HCPs) Who Responded to the Healthcare Professional Global Assessment (HPGA) as "Excellent" at 24 Hours

    Time frame: Up to 24 hours

  31. Percentage of Healthcare Professionals (HCPs) Who Responded to the Healthcare Professional Global Assessment (HPGA) at 48 Hours as "Poor"

    Time frame: Up to 48 hours

  32. Percentage of Healthcare Professionals (HCPs) Who Responded to the Healthcare Professional Global Assessment (HPGA) at 48 Hours as "Fair"

    Time frame: Up to 48 hours

  33. Percentage of Healthcare Professionals (HCPs) Who Responded to the Healthcare Professional Global Assessment (HPGA )at 48 Hours as "Good"

    Time frame: Up to 48 hours

  34. Percentage of Healthcare Professionals (HCPs) Who Responded to the Healthcare Professional Global Assessment (HPGA) at 48 Hours as "Excellent"

    Time frame: Up to 48 hours

  35. Percentage of Healthcare Professionals (HCPs) Who Responded to the Healthcare Professional Global Assessment (HPGA) at 72 Hours as "Poor"

    Time frame: Up to 72 hours

  36. Percentage of Healthcare Professionals (HCPs) Who Responded to the Healthcare Professional Global Assessment (HPGA) at 72 Hours as "Fair"

    Time frame: Up to 72 hours

  37. Percentage of Healthcare Professionals (HCPs) Who Responded to the Healthcare Professional Global Assessment (HPGA) at 72 Hours as "Good"

    Time frame: Up to 72 hours

  38. Percentage of Healthcare Professionals (HCPs) Who Responded to the Healthcare Professional Global Assessment (HPGA) at 72 Hours as "Excellent"

    Time frame: Up to 72 hours

  39. Percentage of Patients Who Terminated From the Study Due to Inadequate Analgesia Over the 24-hour Study Period

    Time frame: Up to 24 hours

  40. Percentage of Patients Who Terminated From the Study Due to Inadequate Analgesia After the 24-hour Study Period and Prior to or During the 48 Hour Study Period

    Time frame: Up to 48 hours

  41. Percentage of Patients Who Terminated From the Study Due to Inadequate Analgesia Prior to or During the 72 Hour Study Period

    Time frame: Up to 72 hours

  42. Time-weighted Summed Pain Intensity Difference (SPID) Over the 24-hour Study Period (SPID24)

    Time frame: Up to 24 hours

    The pain intensity difference (PID) at each evaluation time point after the dose of study drug is the difference in pain intensity at the specific evaluation time point and baseline pain intensity [PID(evaluation time after the first dose) = PI(baseline) - PI(evaluation time after the first dose)]. A pain intensity score ranging from 0 (no pain) to 10 (worst possible pain) is obtained at baseline and at protocol-specified time points throughout the 24 hour period. The time-weighted SPID24 is the time-weighted summed PID over the 24-hour study period. A negative score indicates an increase in pain intensity and a higher score indicates a greater decrease in pain intensity.The scores ranged from - 72 to 204.

  43. Time-weighted Summed Pain Intensity Difference (SPID) Over the 48-hour Study Period (SPID-48) Study Period

    Time frame: Up to 48 hours

    The pain intensity difference (PID) at each evaluation time point after the dose of study drug is the difference in pain intensity at the specific evaluation time point and baseline pain intensity [PID(evaluation time after the first dose) = PI(baseline) - PI(evaluation time after the first dose)]. A pain intensity score ranging from 0 (no pain) to 10 (worst possible pain) is obtained at baseline and at protocol-specified time points and throughout the 48 hour period. The time-weighted SPID48 is the time-weighted summed PID over the 48-hour study period. A negative score indicates an increase in pain intensity and a higher score indicates a greater decrease in pain intensity.The scores ranged from -144 to 408.

  44. Time-weighted Summed Pain Intensity Difference (SPID) Over the 72-hour Study Period (SPID-72) Study Period

    Time frame: Up to 72 hours

    The pain intensity difference (PID) at each evaluation time point after the dose of study drug is the difference in pain intensity at the specific evaluation time point and baseline pain intensity [PID(evaluation time after the first dose) = PI(baseline) - PI(evaluation time after the first dose)]. A pain intensity score ranging from 0 (no pain) to 10 (worst possible pain) is obtained at baseline and at protocol-specified time points throughout the 72 hour period. The time-weighted SPID72 is the time-weighted summed PID over the 72-hour study period. A negative score indicates an increase in pain intensity and a higher score indicates a greater decrease in pain intensity. The scores ranged from -239 to 624.

  45. Total Pain Relief (TOTPAR) Over the 24-hour Study Period (TOTPAR24)

    Time frame: Up to 24 hours

    Total pain relief over the 24-hour study period. A higher TOTPAR score means a greater relief in pain. Range of scores was from 0.00 to 96.00.

  46. Total Pain Relief (TOTPAR) Over the 48-hour Study Period (TOTPAR48)

    Time frame: Up to 48 hours

    Total pain relief over the 48-hour study period. A higher TOTPAR score means a greater relief in pain. Range of scores was from 0.00 to 192.00.

  47. Total Pain Relief (TOTPAR) Over the 72-hour Study Period (TOTPAR72)

    Time frame: Up to 72 hours

    Total pain relief over the 72-hour study period. A higher TOTPAR means a greater relief in pain. Range of scores was from 0.00 to 288.00.

  48. Pain Intensity (PI) at Each Evaluation Time Point

    Time frame: Up to 72 hours

    At protocol-specified time points, the patient is asked to self-record his/her current level of pain on an 11-point numerical rating scale where 0 equals no pain and 10 equals the worst possible pain.

  49. Pain Intensity Difference (PID) at Each Evaluation Time Point

    Time frame: Up to 72 hours

    The PID at each evaluation time point after the dose of study drug is the difference in pain intensity at the specific evaluation time point and baseline pain intensity [PID(evaluation time after the first dose) = PI(baseline) - PI(evaluation time after the first dose)]. The higher the PID score, the lower the pain intensity. The scores ranged from - 239 to 624.

  50. Pain Relief (PR) at Each Evaluation Time Point

    Time frame: Up to 72 hours

    At protocol-specified time points, the patient is asked to self-record his/her current level of pain relief on 5-point numerical rating scale where 0 equaled no pain relief and 4 equaled complete pain relief. The baseline score references the baseline pain intensity score and the following timepoints reference pain relief scores.

  51. Patient Usability Questionnaire (PUQ)

    Time frame: Up to 72 hours

    Questionnaire completed by patients at the end of his/her participation in the study regarding the usability of Zalviso.

  52. Nurse Usability Questionnaire (NUQ)

    Time frame: Up to 72 hours

    Questionnaire regarding the usability of Zalviso completed by HCPs who had set up at least 5 Zalviso Systems for patients

  53. Number of Study Drug Doses Used

    Time frame: Up to 72 hours

  54. Average Hourly Use of Study Drug

    Time frame: Up to 72 hours

    Average number of study drug doses used per hour, adjusting by treatment exposure time and study period

  55. Average Inter-dosing Interval (in Minutes)

    Time frame: Up to 72 hours

  56. Total Amount of Supplemental Morphine (mg) Utilized

    Time frame: Up to 72 hours

    Supplemental opioid medication (2 mg IV morphine) was allowed in the first 30 minutes after the first on-demand dose of study drug had been administered, if necessary, to keep a patient comfortable. Otherwise, supplemental opioid medication (2 mg IV morphine, no more frequently than hourly) was allowed for pain due to ambulation or with the initiation of passive range of motion therapy throughout the remainder of the study.

Sponsors and collaborators

Lead sponsor

Talphera, Inc

Industry

Registry information

Official study title

A Multicenter, Open-Label Trial to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Jan 26, 2016
Registry last updated
Aug 8, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.